Newron Pharmaceuticals SpA has reached a licensing agreement with Merck Serono to investigate the potential of two Merck clinical-stage compounds for disorders of the central nervous system. Financial terms weren’t disclosed.
A Phase-3 study of motesanib, a small molecule antagonist of vascular endothelial growth factor (VEGF) receptors, failed to meet its primary endpoint of improving the overall survival for patients with advanced, non-squamous, non-small cell lung cancer (NSCLC), the sponsor said.
Anergis SA, a privately held Swiss company developing immunotherapy for allergies, has received an endorsement of its technology with a CHF18 million (€14 million) Series “A” venture financing.
The US Food and Drug Administration has approved a new monoclonal antibody, Yervoy (ipilimumab), to treat patients with late-stage melanoma, the most dangerous type of skin cancer. The antibody is manufactured by Bristol-Myers Squibb Inc.
Paion AG more than doubled its revenue in 2010 as a result of milestone payments from three partners relating to progress in the development of desmoteplase for stroke; remimazolam for sedation and glial growth factor 2 (GGF2) for heart failure.
Evotec AG reported both operating and net profits for 2010, the first time in the company’s 18-year history, as it started to reap the rewards of a strategic shift towards drug discovery alliances with other companies instead of solo development.
GlaxoSmithKline Plc said it is withdrawing its regulatory applications for dutasteride (Avodart) which was being investigated to reduce the risk of prostate cancer in men at an increased risk of the disease.
Sanofi-Aventis SA has fixed the terms of its offering of $7 billion of US dollar-denominated notes which will finance its acquisition of Genzyme Corp. The French multinational is acquiring the US company for about $20.1 billion.
Merck & Co Inc and Sanofi-Aventis SA have abruptly ended their agreement to create a joint animal health venture citing difficulties in getting approval from antitrust authorities in different jurisdictions in the world.
Novartis has announced the acquisition of 85% of a privately-held vaccine company in China, Zhejiang Tianyuan Bio-Pharmaceutical Co Ltd. Financial details were not disclosed. The company has an R&D and manufacturing site near Shanghai.